JP4913595B2 - 肺疾患を治療するための粘液活性剤 - Google Patents

肺疾患を治療するための粘液活性剤 Download PDF

Info

Publication number
JP4913595B2
JP4913595B2 JP2006525902A JP2006525902A JP4913595B2 JP 4913595 B2 JP4913595 B2 JP 4913595B2 JP 2006525902 A JP2006525902 A JP 2006525902A JP 2006525902 A JP2006525902 A JP 2006525902A JP 4913595 B2 JP4913595 B2 JP 4913595B2
Authority
JP
Japan
Prior art keywords
particles
mucus
heparin
mucoactive
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006525902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505830A (ja
JP2007505830A5 (enExample
Inventor
デイビッド・モートン
デイビッド・ガンダートン
ジョン・スタニフォース
ヨリック・カムラグ
Original Assignee
ベクトゥラ・グループ・ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0321611.6A external-priority patent/GB0321611D0/en
Application filed by ベクトゥラ・グループ・ピーエルシー filed Critical ベクトゥラ・グループ・ピーエルシー
Publication of JP2007505830A publication Critical patent/JP2007505830A/ja
Publication of JP2007505830A5 publication Critical patent/JP2007505830A5/ja
Application granted granted Critical
Publication of JP4913595B2 publication Critical patent/JP4913595B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006525902A 2003-09-15 2004-09-15 肺疾患を治療するための粘液活性剤 Expired - Fee Related JP4913595B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0321611.6A GB0321611D0 (en) 2003-09-15 2003-09-15 Pharmaceutical compositions
GB0321611.6 2003-09-15
GB0327723.3 2003-11-28
GBGB0327723.3A GB0327723D0 (en) 2003-09-15 2003-11-28 Pharmaceutical compositions
PCT/GB2004/003932 WO2005025540A2 (en) 2003-09-15 2004-09-15 Mucoactive agents for treating a pulmonary disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011243533A Division JP2012031204A (ja) 2003-09-15 2011-11-07 肺疾患を治療するための粘液活性剤

Publications (3)

Publication Number Publication Date
JP2007505830A JP2007505830A (ja) 2007-03-15
JP2007505830A5 JP2007505830A5 (enExample) 2011-08-04
JP4913595B2 true JP4913595B2 (ja) 2012-04-11

Family

ID=34315438

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525902A Expired - Fee Related JP4913595B2 (ja) 2003-09-15 2004-09-15 肺疾患を治療するための粘液活性剤
JP2011243533A Pending JP2012031204A (ja) 2003-09-15 2011-11-07 肺疾患を治療するための粘液活性剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011243533A Pending JP2012031204A (ja) 2003-09-15 2011-11-07 肺疾患を治療するための粘液活性剤

Country Status (15)

Country Link
US (2) US7928089B2 (enExample)
EP (2) EP1663151A2 (enExample)
JP (2) JP4913595B2 (enExample)
KR (1) KR20060082865A (enExample)
CN (1) CN1874757B (enExample)
AU (1) AU2004271778B2 (enExample)
BR (1) BRPI0414425A (enExample)
CA (1) CA2538399A1 (enExample)
GB (1) GB0327723D0 (enExample)
IL (1) IL173987A0 (enExample)
NO (1) NO20061254L (enExample)
NZ (1) NZ545550A (enExample)
RU (1) RU2363448C2 (enExample)
SG (1) SG146649A1 (enExample)
WO (1) WO2005025540A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
ES2848385T3 (es) * 2003-11-12 2021-08-09 Univ Pennsylvania Métodos de uso de gelsolina para tratar o prevenir septicemia bacteriana
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2607686C (en) * 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
MX2009003002A (es) * 2006-09-19 2009-06-01 Discovery Lab Inc Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
CN101433521B (zh) * 2007-11-14 2012-08-08 中国医学科学院药用植物研究所 药用可吸入微粒、使用其的肺部吸入制剂及其制备方法
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
EP2411137B1 (en) 2009-03-27 2016-09-07 Bend Research, Inc. Spray-drying process
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
EP2611530B1 (en) 2010-09-03 2019-01-16 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012073025A1 (en) * 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
WO2013119705A2 (en) * 2012-02-06 2013-08-15 University Of Iowa Research Foundation Method of regulating cftr expression and processing
WO2013176622A1 (en) * 2012-05-21 2013-11-28 Agency For Science, Technology And Research (A*Star) A dry powder formulation
ITMI20121052A1 (it) * 2012-06-18 2013-12-19 Ecupharma Srl Formulazioni inalatorie per la rimozione delle secrezioni viscose dall'apparato respiratorio
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
ES2793905T3 (es) 2014-09-09 2020-11-17 Vectura Ltd Formulación que comprende glicopirrolato, método y aparato
AU2015325055B2 (en) * 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
SI3204095T1 (sl) 2014-10-10 2019-08-30 Ablynx N.V. Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom
RU2017115670A (ru) 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix
CN105920020B (zh) * 2016-06-23 2019-01-08 潘海英 一种治疗肺部疾病的药物组合物及其制备方法和用途
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
AU2017341815B2 (en) * 2016-10-14 2023-06-15 Pulmatrix Operating Company, Inc. Antifungal dry powders
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
TR201722950A2 (tr) * 2017-12-29 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Koah tedavisinde yeni farmasötik bileşimler.
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
JP2022526495A (ja) * 2019-03-18 2022-05-25 シーダーズ－サイナイ・メディカル・センター 胃腸疾患および障害を治療するための組成物およびその方法
JP2022532431A (ja) 2019-05-16 2022-07-14 エアロベイト セラピューティクス， インコーポレイテッド イマチニブ製剤、その製造および使用
KR102250876B1 (ko) * 2019-07-18 2021-05-11 충북대학교 산학협력단 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물
WO2025034892A2 (en) * 2023-08-07 2025-02-13 The University Of North Carolina At Chapel Hill Ultrasound contrast agent for binding with or adhering to respiratory mucus and methods for using same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015672A2 (en) * 1999-08-26 2001-03-08 Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
JP2001511439A (ja) * 1997-08-04 2001-08-14 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 後期アレルギー反応及び炎症性疾患を治療するための方法と組成物
JP2002531487A (ja) * 1998-12-09 2002-09-24 ヴェクトゥラ リミテッド 粉末の改良
JP2003513031A (ja) * 1999-10-29 2003-04-08 インヘール セラピューティック システムズ， インコーポレイテッド 改良された分散性を有する乾燥粉末組成物
JP2003513719A (ja) * 1999-11-05 2003-04-15 パリ ゲゼルシャフトミット ベシュレンクテル ハフツング スペツィアリステン フィア エフェクティブインハレーション 吸入用噴霧器
WO2003068187A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
WO2003068254A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Glycosaminoglycan-dnase combination therapy
WO2003068188A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Combination therapy for respiratory disorders

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734401A (en) 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
JP2736168B2 (ja) 1992-03-10 1998-04-02 フアイソンズ・ピーエルシー 医薬製剤
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
EP0651645B1 (en) * 1992-07-24 2002-02-27 Thomas P. Kennedy Medicament for inhibiting neutrophil elastase and cathepsin g
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
WO1997014407A1 (en) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
NZ332669A (en) 1996-04-29 1999-02-25 Dura Pharma Inc A dry power inhalation system which is flow rate independent
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
RU2198181C2 (ru) * 1997-03-20 2003-02-10 Ново Нордиск А/С Не содержащие цинк кристаллы инсулина для применения в легочных композициях
US20010046974A1 (en) 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
AU7753898A (en) 1997-06-06 1998-12-21 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CA2209342A1 (en) 1997-06-30 1998-12-30 The University Of British Columbia Use of dextran and other oligomeric saccharides to improve airway clearance
IT1296998B1 (it) 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
US20030118514A1 (en) 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
CA2367131C (en) 1999-04-05 2007-07-03 Solomon S. Steiner Methods for fine powder formation
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US6560897B2 (en) 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
JP2003504428A (ja) 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
ES2161615B1 (es) 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
CA2340836A1 (en) 2000-03-18 2001-09-18 Degussa Ag Granular product
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US20050032745A1 (en) 2000-05-04 2005-02-10 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CN1197587C (zh) 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6969705B2 (en) 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2430318C (en) 2000-11-29 2009-10-27 Itoham Foods Inc. Powder formulation and method for producing the same
DK2283818T3 (en) 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
EP1337239B2 (en) 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
IL155920A0 (en) 2000-12-22 2003-12-23 Aspen Aerogels Inc Aerogel powder comprising therapeutic agents
GB0102902D0 (en) 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
GB0106403D0 (en) 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
US20030091513A1 (en) 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
AU2002335046A1 (en) * 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
WO2003072016A2 (en) 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
EP1458361A4 (en) 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
US20060188451A1 (en) 2001-12-21 2006-08-24 Aspen Aerogels, Inc. Aerogel based pharmaceutical formulations
US20030124087A1 (en) 2001-12-26 2003-07-03 Amitie Co. Ltd. Anti-adhesion barrier
AU2003215334A1 (en) * 2002-02-22 2003-09-09 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
FI116657B (fi) 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
JP2005530725A (ja) 2002-04-12 2005-10-13 カンピナ・ネーデルラント・ホールディング・ベスローテン・フェンノートシャップ ドライパウダー吸入製剤において使用する賦形剤
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US20040028746A1 (en) 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20040043064A1 (en) 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
GB0304540D0 (en) 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
US6933372B2 (en) 2003-03-07 2005-08-23 Warner-Lambert Company Method to produce a solid form of heparin
MXPA05012821A (es) 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.
CA2435632A1 (en) 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
WO2005009375A2 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US9345664B2 (en) 2003-09-02 2016-05-24 Norton Healthcare Ltd Process for preparing a medicament
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
WO2005032483A2 (en) 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
EA200600877A1 (ru) 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
CN1261105C (zh) * 2003-12-05 2006-06-28 吉林省辽源亚东药业股份有限公司 一种复方吡拉西坦脑蛋白水解物制剂及制备方法
GB0329208D0 (en) 2003-12-17 2004-01-21 Ici Plc Particulate materials
WO2005061089A1 (en) 2003-12-23 2005-07-07 Niro A/S A method and apparatus for producing micro particles
US7928059B2 (en) * 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
EP1748781B1 (en) 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006033693A2 (en) 2004-06-30 2006-03-30 Deangelis Paul L Methods of selectively treating diseases with specific glycosaminoglycan polymers
US20060014698A1 (en) 2004-07-14 2006-01-19 O'connor Michael F Nebulized pharmaceutical compositions for the treatment of bronchial disorders
GB0416397D0 (en) 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
KR20070111497A (ko) 2005-02-10 2007-11-21 오렉쏘 에이비 약의 경점막 투여에 유용한 새로운 약학 조성물
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
WO2006096906A1 (en) 2005-03-18 2006-09-21 Nanomaterials Technology Pte Ltd Inhalable drug
BRPI0611433A2 (pt) 2005-05-05 2010-09-08 Sanofi Aventis Us Llc formulações estáveis de nanopartìcula
KR101554834B1 (ko) 2005-10-12 2015-09-21 세이가가쿠 고교 가부시키가이샤 점막에 적용하는 작용제 및 그것의 제조 방법
US20070098803A1 (en) 2005-10-27 2007-05-03 Primet Precision Materials, Inc. Small particle compositions and associated methods
US7597094B2 (en) * 2005-11-29 2009-10-06 Leon Monroe Pittman Compound bow maintenance press and method for compressing a compound bow from the bow limb ends
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CA2633254A1 (en) 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Pharmaceutical compositions of ilaprazole
DE102005062270A1 (de) 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
US20070166386A1 (en) 2006-01-13 2007-07-19 Chinea Vanessa I Nanoparticle formation of pharmaceutical ingredients
MX2008012794A (es) 2006-04-03 2008-10-15 Teva Pharma Microparticulas de farmacos.
CN101415405A (zh) 2006-04-04 2009-04-22 Stc.Unm公司 用于药物递送的可溶胀颗粒
WO2008054508A2 (en) 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
US20080181957A1 (en) 2006-06-23 2008-07-31 Min Wei Increased amorphous stability of poorly water soluble drugs by nanosizing
WO2008011051A1 (en) 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
US20090203789A1 (en) 2008-01-31 2009-08-13 Multi Formulations Ltd. Fast Dissolution Amino Acid Composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001511439A (ja) * 1997-08-04 2001-08-14 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 後期アレルギー反応及び炎症性疾患を治療するための方法と組成物
JP2002531487A (ja) * 1998-12-09 2002-09-24 ヴェクトゥラ リミテッド 粉末の改良
WO2001015672A2 (en) * 1999-08-26 2001-03-08 Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
JP2003513031A (ja) * 1999-10-29 2003-04-08 インヘール セラピューティック システムズ， インコーポレイテッド 改良された分散性を有する乾燥粉末組成物
JP2003513719A (ja) * 1999-11-05 2003-04-15 パリ ゲゼルシャフトミット ベシュレンクテル ハフツング スペツィアリステン フィア エフェクティブインハレーション 吸入用噴霧器
WO2003068187A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
WO2003068254A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Glycosaminoglycan-dnase combination therapy
WO2003068188A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Combination therapy for respiratory disorders

Also Published As

Publication number Publication date
AU2004271778B2 (en) 2011-04-21
EP1663151A2 (en) 2006-06-07
NO20061254L (no) 2006-04-11
NZ545550A (en) 2009-03-31
CA2538399A1 (en) 2005-03-24
BRPI0414425A (pt) 2006-11-14
EP2277505A3 (en) 2011-06-15
KR20060082865A (ko) 2006-07-19
JP2012031204A (ja) 2012-02-16
US20110217339A1 (en) 2011-09-08
SG146649A1 (en) 2008-10-30
US7928089B2 (en) 2011-04-19
WO2005025540A2 (en) 2005-03-24
CN1874757B (zh) 2011-03-09
GB0327723D0 (en) 2003-12-31
JP2007505830A (ja) 2007-03-15
AU2004271778A1 (en) 2005-03-24
IL173987A0 (en) 2006-07-05
US20070065373A1 (en) 2007-03-22
CN1874757A (zh) 2006-12-06
EP2277505A2 (en) 2011-01-26
WO2005025540A3 (en) 2005-06-16
RU2006112583A (ru) 2007-11-10
RU2363448C2 (ru) 2009-08-10

Similar Documents

Publication Publication Date Title
JP4913595B2 (ja) 肺疾患を治療するための粘液活性剤
JP6904929B2 (ja) エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US20020086852A1 (en) Method for treating respiratory disorders associated with pulmonary elastic fiber injury
JP2012176990A (ja) 粘膜内壁の生物物理学的な性質を変化させる製剤
AU2010232591A1 (en) Pulmonary and nasal delivery of serum amyloid P
US20100040691A1 (en) Pharmaceutical compositions comprising methotrexate
WO2012061902A1 (en) Micronised spray-dried particles comprising polymyxin
TW201306847A (zh) 組成物及用途
EP3478298B1 (en) Delivery device and formulation
MXPA06002952A (en) Mucoactive agents for treating a pulmonary disease
ZA200602748B (en) Mucoactive agents for treating a pulmonary disease
EP2827877B1 (en) Uses of antagonists of hyaluronan signaling
Li Multi-component Microparticulate/nanoparticulate Dry Powder Inhalation Aerosols for Targeted Pulmonary Delivery

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110315

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111107

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111220

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120119

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150127

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees